These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 17333056)

  • 1. [Lowering LDL cholesterol. How much is enough?].
    März W; Grammer TB
    Internist (Berl); 2007 Mar; 48(3):319-26. PubMed ID: 17333056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group.
    Schrott HG; Bittner V; Vittinghoff E; Herrington DM; Hulley S
    JAMA; 1997 Apr 23-30; 277(16):1281-6. PubMed ID: 9109465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlates of repeat lipid testing in patients with coronary heart disease.
    Virani SS; Woodard LD; Wang D; Chitwood SS; Landrum CR; Urech TH; Pietz K; Chen GJ; Hertz B; Murawsky J; Ballantyne CM; Petersen LA
    JAMA Intern Med; 2013 Aug; 173(15):1439-44. PubMed ID: 23817669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [LDL-cholesterol in secondary prevention: goal-attainment in patients on lipid-lowering drugs in private practice and in hospitals in Austria (ZIEL)].
    Föger B; Patsch JR
    Wien Klin Wochenschr; 2011 Jan; 123(1-2):21-7. PubMed ID: 21165704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Improved coronary vasodilator capacity by drug lipid lowering therapy in patients in the early stage of coronary atherosclerosis with reduced coronary reserves and moderate LDL hypercholesteremia].
    Baller D; Gleichmann U; Notohamiprodjo G; Weise R; Holzinger J; Montanus H; Betker S; Lehmann J
    Z Kardiol; 1998; 87 Suppl 2():136-44. PubMed ID: 9827472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world effectiveness of lipid-lowering therapy in male and female outpatients with coronary heart disease: relation to pre-treatment low-density lipoprotein-cholesterol, pre-treatment coronary heart disease risk, and other factors.
    Krobot KJ; Yin DD; Alemao E; Steinhagen-Thiessen E
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):37-45. PubMed ID: 15703504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Lipid therapy. Prevention of arteriosclerotic cardiovascular diseases].
    Windler E
    Internist (Berl); 2001 Jan; 42(1):92-110. PubMed ID: 11271625
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical inquiries. What does the evidence tell us about treating very-high-risk patients to an LDL <70 mg/dL?
    Nelson C; Hitchcock K; Bohlen JA; Malaty W
    J Fam Pract; 2009 Dec; 58(12):665-7. PubMed ID: 19961822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Lipid lowering therapy for primary prevention of coronary heart disease--pro lipid lowering therapy].
    Steinmetz A; Noll B; Maisch B; Schäfer JR
    Z Kardiol; 1998; 87 Suppl 2():205-9. PubMed ID: 9827484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving optimal lipid goals in patients with coronary artery disease.
    Karalis DG; Subramanya RD; Hessen SE; Liu L; Victor MF
    Am J Cardiol; 2011 Mar; 107(6):886-90. PubMed ID: 21247526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extracorporeal LDL cholesterol removal: role of LDL-pheresis in combination with other hypolipidemic therapy to regress vascular disease.
    Saal SD; Gordon BR; Parker TS; Levine DM; Tyberg TI; Rubin AL
    Am J Med; 1989 Nov; 87(5N):68N-74N. PubMed ID: 2486551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attainment of low-density lipoprotein cholesterol goals in coronary artery disease.
    Kauffman AB; Olson KL; Youngblood ML; Zadvorny EB; Delate T; Merenich JA;
    J Clin Lipidol; 2010; 4(3):173-80. PubMed ID: 21122649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the attainment of current recommended low-density lipoprotein cholesterol goal of less than 70 mg/dl on clinical outcomes in very high-risk patients treated with drug-eluting stents.
    Kim BK; Kim DW; Oh S; Yoon SJ; Park S; Jeon DW; Yang JY
    Coron Artery Dis; 2010 May; 21(3):182-8. PubMed ID: 20168221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Statins for cardiovascular prevention. Lowering LDL cholesterol, the primary objective].
    Fruchart JC
    Presse Med; 2002 Sep; 31(30):1428-33. PubMed ID: 12378980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular basis for cholesterol therapy.
    Rackley CE
    Cardiol Rev; 2000; 8(2):124-31. PubMed ID: 11174884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coronary artery disease prognosis and C-reactive protein levels improve in proportion to percent lowering of low-density lipoprotein.
    O'Keefe JH; Cordain L; Jones PG; Abuissa H
    Am J Cardiol; 2006 Jul; 98(1):135-9. PubMed ID: 16784936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of intensive lipid lowering on coronary atheroma and clinical outcome.
    Houslay ES; Sarma J; Uren NG
    Heart; 2007 Feb; 93(2):149-51. PubMed ID: 17035507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.